<- Go Home

Consun Pharmaceutical Group Limited

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People’s Republic of China.

Market Cap

HKD 10.8B

Volume

2.3M

Cash and Equivalents

HKD 1.3B

EBITDA

HKD 1.4B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

HKD 2.9B

Profit Margin

80.10%

52 Week High

HKD 16.63

52 Week Low

HKD 10.50

Dividend

5.29%

Price / Book Value

2.27

Price / Earnings

9.34

Price / Tangible Book Value

2.40

Enterprise Value

HKD 7.3B

Enterprise Value / EBITDA

5.36

Operating Income

HKD 1.3B

Return on Equity

24.40%

Return on Assets

12.58

Cash and Short Term Investments

HKD 4.0B

Debt

HKD 229.5M

Equity

HKD 5.1B

Revenue

HKD 3.6B

Unlevered FCF

HKD 152.8M

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches